[Results of the Hamburg ovarian blastoma study].
A randomized chemotherapy trial is forthwith reported on, in which therapy A (vincristine/ifosfamide/tegafur) was compared with therapy B (fluorouracil/trofosfamide/methotrexate/melphalan). Both patient groups received trofosfamide and oral progesterone as maintenance treatment until the end of the second therapy year. Forty-six patients were randomized into group A, 63 into group B. The evaluation of the survival curves suggests a division of the patients into 3 groups with different mortality risks.